Regeneron Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1988-01-01

Employees: 13.4K

Market Cap: $132.4B

Website: http://www.regeneron.com

Introduction: Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Clinical Trials

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

Phase 1

Completed

Conditions: Birch Pollen Allergy
Healthy Volunteers

Interventions: Drug: REGN5713-5714-5715
Drug: Matching placebo

First Posted Date: 2019-05-31

Last Posted Date: 2020-04-28

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT03969849

Locations: 🇧🇪
Regeneron Study Site, Leuven, Belgium

Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Phase 3

Recruiting

Conditions: Cutaneous Squamous Cell Carcinoma

Interventions: Drug: Placebo
Drug: Cemiplimab

First Posted Date: 2019-05-31

Last Posted Date: 2024-05-20

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 412

Registration Number: NCT03969004

Locations: 🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France
🇪🇸
Hospital Universitario Virgen Macarena-merge, Sevilla, Spain
🇫🇷
Hospital Saint-Louis - APHP, Paris Cedex 10, France

and more 146 locations

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

Phase 2

Terminated

Conditions: Pain
Osteoarthritis of the Knee

Interventions: Drug: REGN5069
Drug: Matching Placebo

First Posted Date: 2019-05-20

Last Posted Date: 2021-07-01

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 259

Registration Number: NCT03956550

Locations: 🇺🇦
Regeneron Study Site, Kyiv, Ukraine

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Phase 2

Terminated

Conditions: Osteoarthritis, Hip
Osteoarthritis, Knee

Interventions: Drug: Fasinumab
Drug: Naproxen
Drug: Diclofenac
Drug: Celecoxib
Drug: Placebo

First Posted Date: 2019-05-14

Last Posted Date: 2023-10-17

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT03949673

Locations: 🇵🇱
Regeneron Recruting SIte, Bialystok, Poland
🇬🇧
Regeneron Research Site, Liverpool, United Kingdom

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase 2

Completed

Conditions: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions: Drug: REGN3918

First Posted Date: 2019-05-13

Last Posted Date: 2023-06-26

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT03946748

Locations: 🇬🇧
Regeneron Study Site, Airdrie, Lanarkshire, United Kingdom

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

Recruiting

Conditions: Adverse Pregnancy Outcomes
Atopic Dermatitis

Interventions: Drug: dupilumab

First Posted Date: 2019-05-03

Last Posted Date: 2024-10-18

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 3930

Registration Number: NCT03936335

Locations: 🇺🇸
Regeneron Research Site, Boston, Massachusetts, United States

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Phase 2

Active, not recruiting

Conditions: Non-small Cell Lung Cancer
Hepatocellular Carcinoma
Head and Neck Squamous Cell Carcinoma

Interventions: Drug: cemiplimab
Drug: Platinum Doublet
Drug: fianlimab

First Posted Date: 2019-04-16

Last Posted Date: 2025-04-11

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 65

Registration Number: NCT03916627

Locations: 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States

Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma

Phase 1

Recruiting

Conditions: Cutaneous Squamous Cell Carcinoma
Basal Cell Carcinoma

Interventions: Drug: Cemiplimab

First Posted Date: 2019-03-26

Last Posted Date: 2025-04-23

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 113

Registration Number: NCT03889912

Locations: 🇺🇸
Medical Dermatology Specialists, Phoenix, Arizona, United States
🇺🇸
Stanford University School of Medicine, Redwood City, California, United States
🇺🇸
TCR Medical Corporation, San Diego, California, United States

and more 19 locations

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies

Phase 2

Recruiting

Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL)

Interventions: Drug: Odronextamab

First Posted Date: 2019-03-25

Last Posted Date: 2025-04-25

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 576

Registration Number: NCT03888105

Locations: 🇮🇹
Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
🇮🇹
Azienda Ospedaliera Santa Maria Terni, Terni, Italy
🇮🇹
Ospedale dell'Angelo - Varese, Varese, Italy

and more 137 locations

Study in Cat-Allergic Patients With Asthma to Evaluate the Efficacy of a Single Dose of REGN1908-1909 to Reduce Bronchoconstriction Upon Cat Allergen Challenge

Phase 2

Completed

Conditions: Mild Asthma
Cat Allergy

Interventions: Drug: REGN1908-1909
Drug: Placebo

First Posted Date: 2019-02-12

Last Posted Date: 2021-07-01

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 56

Registration Number: NCT03838731

Locations: 🇫🇷
Regeneron Research Site, Strasbourg, France

Home Terms & Conditions Privacy Policy